Mirati gauging sale interest of Big Pharmas — report
Mirati Therapeutics, maker of the experimental cancer drug adagrasib, is piquing the interest of Big Pharmas, according to a report from Bloomberg.
On Tuesday, the biotech’s stock $MRTX rose by almost 16%, jumping from just under $75 to over $86. After Wednesday’s opening bell, Mirati’s stock continued to climb nearly $3 apiece. But that still leaves it down 43% from the beginning of this year, a reflection of the biotech market as a whole.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.